09:35 AM EST - NeonMind Biosciences Inc. : Provided a summary of business highlights on the Company's activities and progress across its Pharmaceutical and Medical Services Divisions. Successfully completed a pre-Investigational New Drug (pre-IND) consultation with the U.S. Food and Drug Administration (FDA) regarding proposed clinical trials for NeonMind's lead obesity drug candidate, NEO-001; Filed four new provisional patent applications with the United States Patent and Trademark Office to protect NeonMind's proprietary data derived from the Company's initial preclinical trial examining the potential use of psilocybin as a treatment for weight loss; Completed an integrated drug development plan for its lead drug candidate targeting obesity, NEO-001; Established a Research and Development Advisory Board and expanded NeonMind's team with regulatory experts to successfully execute its integrated drug development plan and streamline its corporate structure for capital efficiencies. NeonMind Biosciences Inc.
shares C.NEON are trading unchanged at $0.06.
